You are here:

buprenorphine oral lyophilisate (Espranor)

Advice

following an abbreviated submission:

buprenorphine oral lyophilisate (Espranor®) is accepted for restricted use within NHS Scotland.

Indication under review: Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Treatment with buprenorphine oral lyophilisate is intended for use in adults and adolescents aged 15 years or over who have agreed to be treated for addiction.

SMC restriction: to patients in whom methadone is not suitable. 

Buprenorphine oral lyophilisate provides an alternative to buprenorphine/naloxone sublingual (SL) tablets at reduced cost.  The oral lyophilisate formulation has the advantage of a faster dissolution time.

Prescribers should be aware that available buprenorphine preparations are not interchangeable.

Generic buprenorphine SL tablets are available at lower cost.

This SMC advice takes account of the benefit of Patient Access Schemes (PAS) that improves the cost effectiveness of buprenorphine oral lyophilisate.  This advice is contingent upon the continuing availability of these PAS in NHS Scotland or list prices that are equivalent or lower.

Drug Details

Drug Name: buprenorphine oral lyophilisate (Espranor)
SMC Drug ID: 1245/17
Manufacturer: Martindale Pharma
Indication: Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Treatment with buprenorphine oral lyophilisate is intended for use in adults and adolescents aged 15 years or over who have agreed to be treated for addiction.
BNF Category:
Sub Category: 4.10 Drugs used in substance dependance
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 12 June 2017

Back